4
Changes in Ownership
MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0001628280-25-011405
Senior VP, Chief Pharma Dev. sold 14,113 shares at an average $341.32 ($4,817,104)
- Senior VP, Chief Pharma Dev. acquired 14,113 shares (option exercise)
- Senior VP, Chief Pharma Dev. acquired 2,061 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Option exercise | +6,825 | $87.92 | $600,054 | 10,553 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Option exercise | +7,288 | $87.09 | $634,712 | 17,841 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | −900 | $335.15 | $301,631 | 16,941 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | −1,777 | $336.78 | $598,457 | 15,164 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | −1,146 | $338.09 | $387,452 | 14,018 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | −400 | $339.68 | $135,874 | 13,618 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | −1,657 | $340.75 | $564,627 | 11,961 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | −1,043 | $341.84 | $356,537 | 10,918 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | −1,077 | $342.90 | $369,300 | 9,841 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | −4,701 | $343.85 | $1,616,429 | 5,140 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | −1,412 | $344.76 | $486,797 | 3,728 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Grant or award | +2,061 | 5,789 | D | ||
| Derivatives | |||||||
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Option exercise · Stock Option (Right to Buy) | −6,825 | 4,375 | D | ||
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Option exercise · Stock Option (Right to Buy) | −7,288 | 3,062 | D | ||
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2025-03-05 | Grant or award · Stock Option (Right to Buy) | +1,157 | 1,157 | D | ||
| Open-market sales · 14,113 sh · avg $341.32 · $4,817,104 | |||||||
Loading xslF345X05/wk-form4_1741387197.xml…